Vir Biotechnology, Inc. Cost of Revenue
Vir Biotechnology, Inc. (VIR) reported Cost of Revenue of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-05
- Vir Biotechnology, Inc. cost of revenue for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Vir Biotechnology, Inc. cost of revenue for the quarter ending 2025-06-30 was $11.00K, a 78.85% decline year-over-year.
- Vir Biotechnology, Inc. cost of revenue for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Vir Biotechnology, Inc. cost of revenue for the quarter ending 2024-12-31 was $684.00K, a 14.29% decline year-over-year.
- Vir Biotechnology, Inc. cost of revenue for fiscal 2025 was $26.00K, a 96.92% decline from fiscal 2024.
- Vir Biotechnology, Inc. cost of revenue for fiscal 2024 was $845.00K, a 69.44% decline from fiscal 2023.
- Vir Biotechnology, Inc. cost of revenue for fiscal 2023 was $2.77M, a 98.11% decline from fiscal 2022.
- Vir Biotechnology, Inc. cost of revenue for fiscal 2022 was $146.32M, a 122.15% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 6 month | Cost of Revenue 9 month | Cost of Revenue 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | $26.00K 10-K · filed 2026-02-23 | |||
| 2025-06-30 | $11.00K 10-Q · filed 2026-08-05 | $11.00K 10-Q · filed 2026-08-05 | $695.00K derived: sum of 3 quarters · filed 2026-08-05 | $745.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-08 | $684.00K derived: sum of 2 quarters · filed 2026-02-23 | $734.00K derived: sum of 3 quarters · filed 2026-02-23 | $786.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $684.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $734.00K derived: sum of 2 quarters · filed 2026-02-23 | $786.00K derived: sum of 3 quarters · filed 2026-02-23 | $845.00K 10-K · filed 2026-02-23 |
| 2024-09-30 | $50.00K 10-Q · filed 2024-11-04 | $102.00K derived: sum of 2 quarters · filed 2025-08-06 | $161.00K 10-Q · filed 2024-11-04 | $959.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $52.00K 10-Q · filed 2025-08-06 | $111.00K 10-Q · filed 2025-08-06 | $909.00K derived: sum of 3 quarters · filed 2026-02-23 | $947.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $59.00K 10-Q · filed 2025-05-08 | $857.00K derived: sum of 2 quarters · filed 2026-02-23 | $895.00K derived: sum of 3 quarters · filed 2026-02-23 | $917.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | $798.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $836.00K derived: sum of 2 quarters · filed 2026-02-23 | $858.00K derived: sum of 3 quarters · filed 2026-02-23 | $2.77M 10-K · filed 2026-02-23 |
| 2023-09-30 | $38.00K 10-Q · filed 2024-11-04 | $60.00K derived: sum of 2 quarters · filed 2024-11-04 | $1.97M 10-Q · filed 2024-11-04 | $7.96M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $22.00K 10-Q · filed 2024-08-01 | $1.93M 10-Q · filed 2024-08-01 | $7.92M derived: sum of 3 quarters · filed 2025-02-27 | $30.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $1.91M 10-Q · filed 2024-05-03 | $7.90M derived: sum of 2 quarters · filed 2025-02-27 | $30.16M derived: sum of 3 quarters · filed 2025-02-27 | $58.08M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $28.25M derived: sum of 2 quarters · filed 2025-02-27 | $56.17M derived: sum of 3 quarters · filed 2025-02-27 | $146.32M 10-K · filed 2025-02-27 |
| 2022-09-30 | $22.25M 10-Q · filed 2023-11-03 | $50.17M derived: sum of 2 quarters · filed 2023-11-03 | $140.32M 10-Q · filed 2023-11-03 | $197.20M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $27.92M 10-Q · filed 2023-08-04 | $118.07M 10-Q · filed 2023-08-04 | $174.95M derived: sum of 3 quarters · filed 2024-02-26 | $182.78M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $90.15M 10-Q · filed 2023-05-08 | $147.03M derived: sum of 2 quarters · filed 2024-02-26 | $154.86M derived: sum of 3 quarters · filed 2024-02-26 | $156.01M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $56.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $64.71M derived: sum of 2 quarters · filed 2024-02-26 | $65.86M derived: sum of 3 quarters · filed 2024-02-26 | $65.86M 10-K · filed 2024-02-26 |
| 2021-09-30 | $7.84M 10-Q · filed 2022-11-03 | $8.98M derived: sum of 2 quarters · filed 2022-11-03 | $8.99M 10-Q · filed 2022-11-03 | $8.98M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $1.14M 10-Q · filed 2022-08-09 | $1.15M 10-Q · filed 2022-08-09 | $1.14M derived: sum of 3 quarters · filed 2023-02-28 | $1.14M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 derived: sum of 2 quarters · filed 2023-02-28 | $0.00 derived: sum of 3 quarters · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 10-Q · filed 2021-11-04 | $0.00 derived: sum of 2 quarters · filed 2021-11-04 | $0.00 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $0.00 10-Q · filed 2021-08-05 | $0.00 10-Q · filed 2021-08-05 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |